# Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

> **NCT01147081** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 142 (actual)

## Conditions studied

- Seasonal Influenza

## Interventions

- **BIOLOGICAL:** BEGRIVAC

## Key facts

- **NCT ID:** NCT01147081
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2012-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147081, "Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT01147081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*